After only 6 weeks of treatment, gamma glutamyl transpeptidase (GGT) levels were reduced by 23% in the 400mg BID group (p<0.01)
In patients with higher baseline GGT, reduction in GGT levels was even greater with 29% (p<0.01)
Alkaline phosphatase (ALP) levels were reduced by 17% in the 400mg BID group (p<0.001)
To read the press release, please click here.